FilingReader Intelligence
BeOne Medicines reports strong Q2 revenue growth, turns profitable
August 6, 2025 at 10:22 AM UTC•By FilingReader AI
BeOne Medicines reported Q2 2025 revenues of $1.3bn, up 42% from the prior year. The company posted net income of $94.3m versus a loss in Q2 2024.
BRUKINSA sales drove growth, rising 49% globally to $950m. BeOne anticipates over 20 R&D milestones in the next 18 months.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:6160•Hong Kong Exchange
News Alerts
Get instant email alerts when BeiGene publishes news
Free account required • Unsubscribe anytime